Enhancing monitoring of FTD​

There are no FDA approved therapies for FTD, but clinical trials are underway. FTD is a group of disorders characterised by changes to behaviour, language, motor speech, and activities of daily living. 

Redenlab scientists are leading the field of FTD communication research. They partner with global key opinion leaders across natural history studies and treatment trials. Communication is adversely impacted across all FTD phenotypes making it an ideal marker of quality of life and overall disease function. ​

Learn more about our products

Differentiate FTD from other diseases​

The diagnostic journey for people with FTD can be long. The FTD disease profile can be confused with other diseases such as Alzheimer’s and other forms of dementia, with almost 40% of patients initially misdiagnosed. The unique speech and language phenotypes within the FTD spectrum means communication can be used to assist in differential diagnosis.​​

Learn more about our products

Manage your FTD trials with ease​

Redenlab offers a suite of management tools to assess, validate and analyse FTD studies across more than 100 sites globally. Redenlab’s objective markers of speech and language are being used to monitor changes in patient performance, enhancing therapeutic development decisions in your next clinical trial.​

Learn more about our products

Leading analytics among leading academics​

Redenlab partners with the world leading clinician researchers in FTD. Partnerships include:

  • Memory and Aging Center – UCSF, USA​
  • UCL Queen Square Institute of Neurology, UK​
  • Eastern Cognitive Disorders Clinic, Melbourne, Australia​
  • The University of Melbourne, Australia​
  • University of Texas in Austin, USA
Partner with us

Use cases for communication monitoring in FTD​

Post marketing​

CNS health

Communication related quality of life

Treatment efficacy

SCIENCE: Mealtime difficulties following frontotemporal lobar degeneration

    BACKGROUND: Frontotemporal lobar degeneration (FTLD) can result in a decline in behavior, language, and motor function. Mealtime disturbances are a...
    Read more

    SCIENCE: Motor speech signature of behavioral variant frontotemporal dementia: Refining the phenotype

      Comprehensive description of motor speech function in behavioral variant frontotemporal dementia (bvFTD) One in 8 patients presented with moderate speech...
      Read more

      SCIENCE: Motor speech phenotypes of frontotemporal dementia, primary progressive aphasia, and progressive apraxia of speech

        Measures of speech which can assist with diagnosis and classification in FTD, PPA, and progressive apraxia of speech.   Click...
        Read more

        Latest news and updates

        Redenlab at the 2nd Annual Lysosomal Disease Summit 2024

        • Posted on 14 October, 2024
          Redenlab is pleased to announce that Dr. Adam Vogel, an expert in speech and language function, will be presenting at the 2nd Annual Lysosomal Disease Summit, held at the Pullman & Mercure Melbourne Albert Park,...
          Read more

          Redenlab at the Digital Health and AI Innovation Summit 2024

          • Posted on 4 September, 2024
            Dr. Adam Vogel, CSO of Redenlab, will be speaking alongside Dr. Tairmae Kangarloo, Associate Director of Digital Strategy at Takeda, on the topic of “Remote Monitoring of Speech and Voice as Clinical Markers of Health”...
            Read more
            See More Articles